4.5 Article

Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells

期刊

ACS MEDICINAL CHEMISTRY LETTERS
卷 5, 期 7, 页码 782-786

出版社

AMER CHEMICAL SOC
DOI: 10.1021/ml500128g

关键词

alpha-Synuclein; BDNF; ceramides; Parkinson's; PP2A; synucleinopathy; triphenylphosphonium

资金

  1. National Institutes of Health, NINDS [R01-NS42094]
  2. TTUHSC
  3. Coldwell Foundation
  4. Ministry of Education of China [BS2010YY036]

向作者/读者索取更多资源

alpha-Synuclein is a chaperone-like protein implicated in Parkinson's disease (PD). Among alpha-synudein's normal functions is an ability to bind to and stimulate the activity of the protein phosphatase 2A (PP2A) catalytic subunit in vitro and in vivo. PP2A activity is impaired in PD and in dementia with Lewy Bodies in brain regions harboring alpha-synudein aggregates. Using PP2A as the readout, we measured PP2A activity in response to a-synudein, ceramides, and FTY720, and then on the basis of those results, we created new FTY720 compounds. We then measured the effects of those compounds in doparminergic cells. In addition to stimulating PP2A, all three compounds stimulated the expression of brain derived neurotrophic factor and protected MN9D cells against tumor-necrosis-factor-alpha-associated cell death. FTY720-C2 appears to be more potent while FTY720-Mitoxy targets mitochondria. Importantly, FTY720 is already FDA approved for treating multiple sclerosis and is used clinically worldwide. Our findings suggest that FTY720 and our new FTY720-based compounds have considerable potential for treating synucleinopathies such as PD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据